亿帆医药(002019) - 2024 Q4 - 年度业绩预告

Financial Performance - The estimated net profit for 2024 is projected to be 37,600,000 CNY, compared to a loss of 55,107,310 CNY in the same period last year[2] - The estimated net profit after deducting non-recurring gains and losses is projected to be 23,800,000 CNY, up from a loss of 53,262,860 CNY in the previous year[2] - The basic earnings per share is expected to be 0.31 CNY, compared to a loss of 0.45 CNY per share in the same period last year[2] Factors Contributing to Profitability - The significant increase in net profit is attributed to higher sales volume of both new and existing pharmaceutical products, leading to increased gross profit[4] - The company expects a substantial reduction in asset impairment losses compared to the previous year, contributing to improved profitability[4] Cautionary Notes - The financial data provided is preliminary and has not yet been audited by the registered accounting firm, emphasizing the need for cautious investment decisions[5]